SCHEMBL2962034

SCHEMBL2962034

CC(=O)Nc1ccc(Sc2ccccc2)c(N)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 2/20 0.47
NAPRT Q6XQN6 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPT P10636 6/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
KMT2A Q03164 3/20 0.46
TAAR1 Q96RJ0 1/20 0.46
POLB P06746 1/20 0.46
HDAC1 Q13547 2/20 0.45
MEN1 O00255 2/20 0.44
PABPC1 P11940 1/20 0.44
MAOA P21397 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811377 0.81 ALDH1A1 (0.56) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL2021181 0.81 MAPT (0.53) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL2961977 0.81 HSD17B10 (0.55) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL2971539 0.80 HDAC1 (0.53) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL29594647 0.80 TDP1 (0.53) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL8920481 0.80 TDP1 (0.53) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL1454472 0.79 CACNA1B (0.48) KDM4EALDH1A1HSD17B10MAPTKMT2A
SCHEMBL11957604 0.79 MAPT (0.47) KDM4EALDH1A1HSD17B10TDP1MAPT
SCHEMBL2968592 0.78 MEN1 (0.51) KDM4EALDH1A1NPC1RAB9AKMT2A
SCHEMBL2960875 0.78 MAPT (0.70) KDM4EALDH1A1TDP1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
CN-102702194-A Anti-viral compounds ABBOTT LAB 2012-10-03 CN disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
CN-101384592-A Antiviral compounds ABBOTT LAB (US) 2009-03-11 CN disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 KDM4E 1822/4885ALDH1A1 2723/4885HSD17B10 1572/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 KDM4E 1822/4885ALDH1A1 2723/4885HSD17B10 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.